Chargement en cours...
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Recently, two studies using ipilimumab, an anti-CTLA-4 monoclonal antibody (mab) demonstrated improvements in overall survival in the treatment of advanced melanoma. These studies utilized two different schedules of treatment in different patient categories (first and second line of treatment). Howe...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BioMed Central
2011
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3262765/ https://ncbi.nlm.nih.gov/pubmed/22077981 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-9-196 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|